Company news
Voyager Therapeutics, Inc. news in 2021
Voyager Therapeutics, Inc.'s news releases, calls and decks from 2021, newest first.
Voyager Therapeutics Announces Positive Preclinical Data from New Vectorized anti-HER2 Antibody Program at the 26th Society for Neuro-Oncology Annual Meeting
November 18, 2021
Voyager Therapeutics Reports Third Quarter 2021 Financial and Operating Results
November 1, 2021
Voyager Therapeutics Presents Positive Preclinical Data Supporting CNS-Directed GBA1 Gene Therapy at Virtual Congress of the European Society of Gene and Cell Therapy
October 19, 2021
Voyager Therapeutics Announces License Option Agreement with Pfizer for Next-Generation TRACERᵀᴹ AAV Capsids to Enable Neurologic and Cardiovascular Gene Therapy Programs
October 5, 2021
Voyager Therapeutics Transforms Pipeline and Increases Investment in Next-Generation TRACER™ AAV Capsid and Vectorized Antibody Platform Technologies
August 8, 2021
Voyager Therapeutics Announces Strategic Shift and Leadership Transitions
May 18, 2021
Voyager Therapeutics’ Novel Capsids Demonstrate Robust Delivery Across the Blood Brain Barrier, Widespread CNS Transduction in Non-Human Primates
May 10, 2021
Voyager Therapeutics Announces First Quarter 2021 Financial Results and Corporate Updates
May 9, 2021
Voyager Therapeutics Announces Upcoming Data Presentations at the American Society of Gene and Cell Therapy Virtual 2021 Annual Meeting
April 27, 2021
Voyager Therapeutics Receives FDA Clearance of IND Application for Gene Therapy Candidate VY-HTT01 for Treatment of Huntington’s Disease
April 25, 2021
Voyager Therapeutics Announces Fourth Quarter and Full Year 2020 Financial Results and Corporate Updates
February 24, 2021
Voyager Therapeutics to Report Fourth Quarter and Full Year 2020 Financial Results and Participate in Upcoming Investor Conference
February 17, 2021